Search

Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
Sarepta Therapeutics to Present at the UBS Biopharma Conference
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference